RxDoctor Payments Data

Sara Iskandar

Internal Medicine · Boca Raton, FLNPI 1104329242

Payments from drug & device makers

$1,842in general payments, 2019–2025

Across 89 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$381
  • Amgen$309
  • Lilly USA, LLC$248
  • Novo Nordisk$152
  • Novartis$112
  • Amneal Pharmaceuticals LLC$81
  • plus $560 from 21 others

What the payments were for

  • Food & beverage$1,842100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,842 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$97,207
Medicare patients
376
Services billed
1,002

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide58$61,264
OzempicSemaglutide22$24,319
EliquisApixaban21$23,557
JanuviaSitagliptin Phosphate15$15,149
SynthroidLevothyroxine Sodium27$2,318
Levothyroxine Sodium124$1,389
Atorvastatin Calcium152$1,381
Rosuvastatin Calcium80$1,022
Duloxetine Hcl25$936
Trazodone Hcl32$828
Amlodipine Besylate119$779
Metoprolol Succinate61$713
ValacyclovirValacyclovir Hcl20$662
Pantoprazole Sodium45$589
Losartan Potassium66$579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$248$61,26458 claims
Novo NordiskOzempic$152$24,31922 claims
PfizerEliquis$14$23,55721 claims
MerckJanuvia$12$15,14915 claims
AbbVieSynthroid$38$2,31827 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$81$1,389124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →